Accidente isquémico transitorio tras espaciar la dosis de alirocumab¿es recomendable reducir las dosis de iPCSK9 ante c-LDL muy bajos?

  1. Piqueras Ruiz, Sandra 1
  2. Parra Virto, Alejandro
  3. Torres do Rego, Ana
  4. Demelo Rodríguez, Pablo
  5. Álvarez-Sala Walther, Luis 2
  1. 1 Departamento de Medicina Interna, Hospital General Universitario Gregorio Marañón, Madrid, España
  2. 2 Unidad de Riesgo Cardiovascular y Lípidos, Departamento de Medicina Interna, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, España
Aldizkaria:
Clínica e investigación en arteriosclerosis

ISSN: 0214-9168,  1578-1879

Argitalpen urtea: 2020

Alea: 32

Zenbakia: 1

Orrialdeak: 30-32

Mota: Artikulua

DOI: HTTPS://DOI.ORG/10.1016/J.ARTERI.2019.04.003 DIALNET GOOGLE SCHOLAR

Beste argitalpen batzuk: Clínica e investigación en arteriosclerosis

Laburpena

Inhibitors of the protein PCSK9, available since 2015, are capable of reducing the concentration of low density lipoprotein cholesterol by 40 to 70%, thus reducing the cardiovascular risk. The present case reports an adverse cardiovascular event that appeared when spacing out the administration of lipid-lowering treatment. A discussion will be presented on the importance of maintaining low cholesterol levels in order to achieve a greater benefit, according to the latest published clinical studies.

Datuen iturria: Dialnet